Zoetis Inc. (NYSE:ZTS) Shares Sold by Brown Lisle Cummings Inc.

Brown Lisle Cummings Inc. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,735 shares of the company’s stock after selling 65 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Zoetis were worth $446,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Rockline Wealth Management LLC lifted its holdings in shares of Zoetis by 4.5% during the fourth quarter. Rockline Wealth Management LLC now owns 5,823 shares of the company’s stock worth $949,000 after purchasing an additional 252 shares during the period. Calamos Wealth Management LLC raised its position in Zoetis by 21.0% during the 4th quarter. Calamos Wealth Management LLC now owns 84,030 shares of the company’s stock worth $13,691,000 after buying an additional 14,568 shares during the last quarter. Calamos Advisors LLC lifted its stake in shares of Zoetis by 15.0% in the 4th quarter. Calamos Advisors LLC now owns 210,885 shares of the company’s stock worth $34,359,000 after acquiring an additional 27,579 shares during the period. Childress Capital Advisors LLC boosted its holdings in shares of Zoetis by 30.6% in the fourth quarter. Childress Capital Advisors LLC now owns 1,599 shares of the company’s stock valued at $261,000 after acquiring an additional 375 shares in the last quarter. Finally, Alliance Wealth Advisors LLC UT increased its stake in shares of Zoetis by 23.1% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 19,720 shares of the company’s stock worth $3,213,000 after acquiring an additional 3,700 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Morgan Stanley decreased their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus price target of $215.00.

Zoetis Stock Performance

Shares of ZTS opened at $171.93 on Tuesday. The company has a 50-day moving average of $169.62 and a two-hundred day moving average of $179.44. The stock has a market cap of $77.57 billion, a P/E ratio of 32.32, a PEG ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.36 EPS. As a group, research analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio is currently 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.